Edesa Biotech Stock Today
| EDSA Stock | USD 1.89 0.06 3.28% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Edesa Biotech is trading at 1.89 as of the 30th of January 2025, a 3.28 percent increase since the beginning of the trading day. The stock's open price was 1.83. Edesa Biotech has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 12th of March 2023 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 2015 | Category Healthcare | Classification Health Care |
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. The company has 3.47 M outstanding shares of which 4.73 K shares are currently shorted by private and institutional investors with about 0.76 trading days to cover. More on Edesa Biotech
Moving together with Edesa Stock
| 0.89 | JNJ | Johnson Johnson | PairCorr |
| 0.74 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.62 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Moving against Edesa Stock
Edesa Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEdesa Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edesa Biotech's financial leverage. It provides some insight into what part of Edesa Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Edesa Biotech (EDSA) is traded on NASDAQ Exchange in USA. It is located in 100 Spy Court, Markham, ON, Canada, L3R 5H6 and employs 16 people. Edesa Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.34 M. Edesa Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.47 M outstanding shares of which 4.73 K shares are currently shorted by private and institutional investors with about 0.76 trading days to cover.
Edesa Biotech currently holds about 12.81 M in cash with (4.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83.
Check Edesa Biotech Probability Of Bankruptcy
Ownership AllocationEdesa Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Edesa Ownership Details
Edesa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 19.0 | |
| Bank Of America Corp | 2024-09-30 | 19.0 | |
| Ubs Group Ag | 2024-09-30 | 4.0 | |
| Crédit Agricole S.a. | 2024-09-30 | 1.0 | |
| Allsquare Wealth Management Llc | 2024-09-30 | 1.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Fmr Inc | 2024-06-30 | 0.0 | |
| Cibc World Markets Inc. | 2024-09-30 | 0.0 | |
| Cm Management, Llc | 2024-09-30 | 110 K | |
| Geode Capital Management, Llc | 2024-09-30 | 20.8 K | |
| Vanguard Group Inc | 2024-09-30 | 15.9 K |
Edesa Biotech Historical Income Statement
Edesa Stock Against Markets
Edesa Biotech Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA CPA | Chief Officer | Profile | |
| Dr MBA | President | Profile | |
| Gary Koppenjan | VP Communications | Profile | |
| MD FRCPC | Company CEO | Profile | |
| Rajan Puri | VP Manufacturing | Profile | |
| BA CA | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.